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Introduction {#s1}
============

Lead is an environmental pollutant whose widespread use has caused extensive environmental contamination and health effects throughout the world ([@c39]). Lead affects multiple body systems, and there is no known level of lead exposure that is considered safe ([@c39]). Lead can pass freely across the placenta ([@c8]), and as a result, there is substantial concern about the potential adverse effects of prenatal lead exposure on the developing fetus. Fetal and early-life exposure to lead, even at low levels, has been associated with a range of adverse health outcomes, including preterm delivery and small-for-gestational-age birth ([@c17]; [@c26]), poor growth in childhood ([@c1]), impaired cognitive and behavioral functions ([@c4]; [@c22]; [@c38]), and hematopoietic system toxicity ([@c15]; [@c34]). Interestingly, sex differences in lead exposure--related health effects have been reported in previous studies ([@c1]; [@c5]; [@c26]; [@c31]; [@c38]), suggesting sexually dimorphic responses to lead exposure between males and females.

Previous animal, *in vitro*, and epidemiological studies have suggested that DNA methylation may be one of the mechanisms by which lead exposure exerts its biological effects. For example, lead exposure induced dose- and sex-specific responses in DNA methylation at several specific loci that were responsible for phenotypes including weight and coat color in mice ([@c11]). An *in vitro* study showed that lead exposure reduces the global DNA methylation level by noncompetitive inhibition and alteration of DNA methyltransferase (*DNMT*) expression ([@c29]), whereas additional animal studies also found that lead exposure affects the expression of maintenance enzyme DNMT1 and the *de novo* methyltransferase DNMT3a in the brain ([@c32]; [@c31]). Specifically, an *in vitro* study demonstrated that lead exposure induced changes in the methylation status of genes involved in neurogenetic signaling pathways in human embryonic stem cells and altered their neuronal differentiation ([@c33]). These studies provide evidence that lead exposure may affect both global and brain genomic methylation. In addition, a recent epidemiological study found that the epigenome-wide DNA methylation profile in umbilical cord blood was associated with high levels of prenatal lead exposure in 127 mother--infant pairs in lead-endemic regions outside the United States ([@c10]).

Although existing evidence supports the role of lead exposure in modifying DNA methylation, little is known about potential effects of relatively low levels of lead exposure *in utero*---common to much of the U.S. population---on DNA methylation. It is also unknown whether variation in DNA methylation associated with prenatal lead exposure may last over time, which may help elucidate the long-term health effects of lead exposure. We aimed to investigate these questions by performing an epigenome-wide association study (EWAS) of low-level maternal lead exposure \[$< 5\;\mu g/\text{dL}$ in red blood cells (RBC)\] and DNA methylation profiles in umbilical cord blood samples from 268 mother--infant pairs enrolled in Project Viva, a U.S.-based prebirth cohort, overall and separately among boys and girls. We also attempted to replicate the observed prenatal lead exposure--cord blood DNA methylation associations using data collected during midchildhood for 240 children (7--10 y of age).

Methods {#s2}
=======

Study Subjects {#s2.1}
--------------

Study subjects were mother--infant pairs in Project Viva, a prospective prebirth cohort with 2,128 women recruited between 1999 and 2002 from Atrius Harvard Vanguard Medical Associates in eastern Massachusetts. Eligibility criteria included English speaking, singleton pregnancy, and $< 22\;{wk}$ of gestation. All women provided written informed consent, and the research was approved by the Institutional Review Board at Harvard Pilgrim Health Care.

We collected blood samples from 1,614 women at an average of 27.9 wk of gestation and analyzed blood samples for 952 women for lead, selecting those with children who participated in follow-up visits in midchildhood. We measured genome-wide DNA methylation using the Infinium HumanMethylation450 (HM450K) BeadChip (Illumina, Inc.) for 507 umbilical cord blood samples collected at delivery and 473 child blood samples collected during midchildhood. A total of 485 cord blood samples and 460 midchildhood blood samples passed quality-control (QC) procedures (see Table S1). Among these, 269 samples had data on both maternal RBC lead and DNA methylation in cord blood, and 241 samples had data on both maternal RBC lead and DNA methylation in midchildhood blood samples. We excluded one sample with undetectable maternal RBC lead, leaving 268 cord blood samples and 240 midchildhood blood samples for the data analysis. Participants with cord blood samples and midchildhood blood samples ($n = 377$, with 131 overlapped between delivery and midchildhood) were generally similar in baseline characteristics compared with those who were not included ($n = 1,751$, data not shown). However, women included in this analysis were more likely to be white (76% vs. 65%) and to have a college degree (70% vs. 64%) than those who were excluded.

Sample Collection {#s2.2}
-----------------

All blood samples were collected in vacutainer tubes containing ethylenediaminetetraacetic acid (EDTA) and were put on ice immediately. The tubes were centrifuged at $1,700 \times \mathit{g}$ for 10 min at 4°C to separate plasma, nucleated cells (including leukocytes and nucleated RBC in cord blood and leukocytes in maternal blood), and RBC within 24 h after collection. We extracted genomic DNA from the nucleated cells with commercially available PureGene Kits (Fisher, Catalog Nos. A407-4, A416-4; Qiagen, Catalog Nos.158908, 158912, 158924). Sample aliquots were then stored at $- 80{^\circ}C$ until analysis.

Measurement of RBC Lead {#s2.3}
-----------------------

Lead concentrations in RBC from prenatal blood samples were measured at the Trace Metals Laboratory at Harvard T.H. Chan School of Public Health in Boston, Massachusetts. RBC samples were weighed and digested for 24 h in $2\;{mL}$ of concentrated nitric acid and $1\;{mL}$ of 30% hydrogen peroxide per $1\; g$ of RBC. Samples were then diluted to a volume of $10\;{mL}$ with deionized water and were measured using a dynamic reaction cell--inductively coupled plasma mass spectrometer (Elan DRC II; PerkinElmer) for lead concentrations. Quality-control measures included analysis of initial and continuous calibration verification standards, 1-ppb lead standard, procedural blanks, QC standard \[National Institute of Standards and Technology Standard Reference Material (NIST SRM) 1643d, Trace Elements in Water (NIST SRM955b, Lead in Blood)\]. Results were calculated as the mean of five replicate measurements. The limit of detection for this procedure was $0.2\,\text{ng}/{mL}$ in RBC.

Epigenome-Wide DNA Methylation Profiling and Quality Controls {#s2.4}
-------------------------------------------------------------

Extracted DNA underwent bisulfite modification using the Zymo EZ DNA Methylation kit (Zymo Research). We randomized samples of bisulfite-modified DNA ($1\;\mu g$ for each sample) across different plates and BeadChips to ensure balance by sex and to reduce the influence of batch effects. Epigenome-wide DNA methylation analysis using the HM450K microarray interrogates 482,397 methylation loci at single-nucleotide resolution. The microarray measurements were processed at Illumina, Inc. We preprocessed data using the *minfi* package in R software (R Project for Statistical Computing). We excluded samples if they *a*) were replicates; *b*) were of low quality with individual call rate $< 0.98$; *c*) had genotype mismatch; or *d*) had sex mismatch (see Table S1). We excluded methylation probes if *a*) they were on either the X or the Y chromosome; *b*) they were nonCpG probes; *c*) they had nonsignificant detection *p*-values ($p > 0.05$) for $> 1\text{\%}$ of the samples; *d*) they had been identified as cross-hybridizing with other genomic locations ([@c6]); or *e*) single nucleotide polymorphism (SNP)-associated probes at either the single base extension or within the target region for SNPs that have a minor allele frequency (MAF) $\geq 0.05$. A total of 394,460 autosomal probes passed the QC. We performed background correction and dye-bias equalization using the normal-exponential out-of-band (*noob*) correction method ([@c37]). We performed a probe type normalization using the beta-mixture quantile (BMIQ) method in the *minfi* package in R ([@c36]).

Covariates {#s2.5}
----------

We collected maternal demographics including age, race/ethnicity, educational level, parity history, and pregnancy health information including smoking status and prepregnancy weight and height, as well as infant sex using self-administered questionnaires and interviews during pregnancy. We collected information on delivery date from medical records. Prepregnancy body mass index (BMI; kilograms per square meter) was calculated from self-reported prepregnancy weight and height. Women reported their last menstrual period (LMP) at enrollment, and we calculated gestational age by subtracting the LMP date from the delivery date or by ultrasound when available and when it differed from the LMP by more than 10 d ([@c12]). To estimate cell-type distribution in blood samples, we used a reference panel of nucleated cells (leukocytes and nucleated RBC) isolated from cord blood ([@c3]) for cord blood samples and an adult leukocyte reference panel for blood samples collected in midchildhood as implemented in *minfi* ([@c2]; [@c28]). Leukocytes included $\text{CD}8^{+}$ T cells, $\text{CD}4^{+}$ T cells, natural killer (NK) cells, monocytes, and B cells.

Statistical Analysis {#s2.6}
--------------------

We accounted for batch effects from plates and for other potential sources of technical variability in the *noob*-adjusted and BMIQ-normalized cord blood methylation data using the ComBat adjustment ([@c18]). We visually inspected the effectiveness of the removal of batch effects using principal component analysis before and after technical batch adjustment.

ComBat-adjusted cord blood methylation $\beta$-values were $\log_{2} - \text{transformed}$ to M-values to be more appropriate for differential analysis of DNA methylation ([@c9]). Robust linear regression models were constructed using the *MASS* package in R, with M-values included as dependent variables and $\log_{2} - \text{transformed}$ maternal RBC lead levels as the main predictor, with adjustment for other potential confounders. Covariates included child sex, gestational age (weeks; as a continuous variable), maternal prepregnancy BMI (kilograms per square meter; as a continuous variable), age at enrollment (years; as a continuous variable), parity history (nulliparous, nonnulliparous), educational level (college graduate, noncollege graduate), smoking status during pregnancy (never, former, current smoker), race (white, nonwhite), and blood cell type distribution in cord blood.

To account for multiple testing, we only report top loci with a false discovery rate (FDR)-corrected $p - \text{value} < \; 0.05$, as has commonly been implemented in previous EWAS analyses ([@c10]; [@c33]). To facilitate interpretation of the results, we report effect estimates in the main text using the $\beta$-value scale for top loci with an $\text{FDR} < \; 0.05$ based on the robust linear regression. We further stratified the EWAS by child sex, using the same criterion of $\text{FDR} < \; 0.05$ to determine the top loci. We tested the interaction between child sex and lead by adding a multiplicative term in the model along with their main effect terms for all significant loci meeting the criterion $\text{FDR} < \; 0.05$.

We attempted to replicate the identified associations for top loci in cord blood by further examining associations of prenatal lead exposure with DNA methylation at the same top CpGs in midchildhood blood samples. For these analyses, we again performed robust linear regression analyses with adjustment for the same covariates \[but using Houseman blood cell type algorithms based on an adult blood cell reference panel ([@c2]; [@c28])\] as well as for child age at blood sample collection. We drew visualized regional DNA comethylation patterns for identified potential target genes using the *coMET* package in R. To address the potential residual confounding due to smoking, we first performed sensitivity analyses excluding infants with sustained maternal smoking during pregnancy ($n = 7$) according to a definition reported elsewhere ([@c20]). We further created a methylation score predicting smoking status by calculating the linear combination of methylation values of 28 CpGs as described elsewhere ([@c27]), and we adjusted for the score as a quartile-covariate instead of adjusting for the smoking status in the EWAS analyses. Finally, we used the *bumphunter* package from Bioconductor to perform a *bumphunting* analysis, as previously described ([@c16]), to detect any differentially methylated regions (DMRs) relative to prenatal maternal lead exposure. Briefly, we fit models with adjustment for the same covariates as in the primary EWAS analyses and ran *bumphunter* on the $\beta$-values using $\log_{2} - \text{transformed}$ RBC-lead as the exposure of interest. All statistical analyses were performed using R 3.2.3 (R Project for Statistical Computing).

Results {#s3}
=======

Among the 268 mothers included in the primary analysis, 138 (51.5%) had female infants ([Table 1](#t1){ref-type="table"}). The mean age of women at enrollment was 31.9 y; 51.1% were nulliparous, 79% were white, and 69.0% were college graduates. The mean maternal RBC blood lead level was $1.22\;\mu g/\text{dL}$ \[standard deviation (SD), 0.63; range, 0.29--4.97\] and was generally similar between mothers of female ($1.24\;\mu g/\text{dL}$) and male ($1.19\;\mu g/\text{dL}$) infants (Wilcoxon rank test $p = 0.30$, see Table S2). This level approximates to a whole-blood level of $0.50\;\mu g/\text{dL}$ based on the estimate that RBC concentrations are the products of the whole-blood level divided by hematocrit ($\sim 40\%$ in women) ([@c8]). Characteristics of the 240 mother--child pairs with child blood samples in midchildhood were largely similar. The mean age of children in midchildhood was 7.9 y (SD, 0.8; range, 7--10).

###### 

Characteristics of Project Viva mother--infant pairs with umbilical cord blood and midchildhood blood methylation measurement.

Table 1 lists characteristics in the first column; the corresponding n values for birth (n equals 268) and midchildhood (n equals 240) are listed in the other columns.

  Characteristic                                    Birth ($n = 268$)   Midchildhood ($n = 240$)
  ------------------------------------------------- ------------------- --------------------------
  Maternal                                                               
   Prepregnancy BMI, ${{kg}/m}^{2}$: Mean (SD)      24.2 (5.0)          24.5 (4.9)
   Age at enrollment, years: Mean (SD)              31.9 (4.7)          32.1 (5.3)
   Nulliparous: $n$ (%)                             131 (48.9)          113 (47.1)
   College graduate: $n$ (%)                        185 (69.0)          169 (70.4)
   Smoking status: $n$ (%)                                               
    Never                                           178 (66.4)          168 (70.0)
    Former                                          55 (20.5)           47 (19.6)
    During pregnancy                                35 (13.1)           25 (10.4)
   Maternal white race/ethnicity: $n$ (%)           212 (79.1)          173 (72.1)
   2nd-trimester Pb, $\mu g/\text{dL}$: Mean (SD)   1.22 (0.63)         1.20 (0.53)
  Child                                                                  
   Female: $n$ (%)                                  138 (51.5)          121 (50.4)
   Gestational age at birth, wk: Mean (SD)          39.7 (1.6)          39.5 (1.7)
   Age at blood collection, years: Mean (SD)        --                  7.9 (0.8)

Note: BMI, body mass index; Pb, lead; SD, standard deviation.

Our analysis showed that the *p*-value distribution of all CpGs was generally similar to the theoretical distribution among all newborns and female infants (in quantile--quantile plots, $\lambda$ values were 0.9308 and 1.0192, respectively) and was slightly different from the theoretical distribution among male infants ($\lambda = 0.7967$; see Figure S1). We found that methylation levels at four CpGs demonstrated significant negative associations ($\text{FDR} < \; 0.05$) with maternal RBC lead among all newborns ([Table 2](#t2){ref-type="table"}; see also Figure S2A). Among these CpGs, one (cg10773601) was annotated to $< 1,500$ bps from the transcription start site of C-Type Lectin Domain Family 11, Member A (*CLEC11A*). For each doubling increase in maternal RBC lead levels, there was a 1.4% decrease in the methylation level of cg10773601 in cord blood ($p = 2.3 \times 10^{- 07}$). This association appeared to be linear over the lead exposure range ([Figure 1A](#f1){ref-type="fig"}). This effect estimate attenuated to $- 0.5\%$ in midchildhood blood samples ($p = 0.12$; see Table S3). Effect estimates for the other three loci in cord blood and midchildhood blood samples were generally minimal and were not annotated to any genes.

![Scatterplots for prenatal red blood cell lead levels and cg10773601 (left panel) and cg24637308 (right panel) methylation levels of umbilical cord blood DNA among all newborns (*A*), male infants (*B*), and female infants (*C*).](EHP1246_f1){#f1}

###### 

CpGs with DNA methylation levels in umbilical cord blood associated with prenatal maternal red blood cell lead concentrations in analyses for all newborns, male infants, and female infants (selected based on $\text{FDR} < \; 0.05$ for EWAS).

Table 2 lists CpG in the first column. The corresponding Chr, position, relation to island, gene, relation to gene, and n (percent) of average methylation are listed in the following columns; the effect estimate (SE) and p value for all newborns, male infants, and female infants, and the p value for interaction are listed in the other columns.

  CpG                                      Chr     Position    Relation to island   Gene          Relation to gene   Average methylation (%)[^*a*^](#t2n1){ref-type="table-fn"}   All newborns      Male infants            Female infants     *p*-Value for interaction                                             
  ---------------------------------------- ------- ----------- -------------------- ------------- ------------------ ------------------------------------------------------------ ----------------- ----------------------- ------------------ --------------------------- ----------------- ----------------------- -----------------------
  Top loci identified for all newborns                                                                                                                                                                                                                                                                               
   cg02272457                              chr6    42427790    Open Sea             --            --                 99.1                                                         $- 0.1$ (0.02)    $1.2 \times 10^{- 6}$   $- 0.1$ (0.03)     $4.1 \times 10^{- 3}$       $- 0.1$ (0.02)    $1.2 \times 10^{- 4}$   0.88
   cg20324491                              chr7    149128397   N_Shore              --            --                 94.2                                                         $- 0.5$ (0.1)     $8.3 \times 10^{–8}$    $- 0.4$ (0.2)      $3.5 \times 10^{–2}$        $- 0.4$ (0.1)     $7.9 \times 10^{- 5}$   0.55
   cg22112000                              chr7    5647182     Island               --            --                 98.5                                                         $- 0.1$ (0.02)    $1.1 \times 10^{- 7}$   $- 0.1$ (0.03)     $5.0 \times 10^{- 3}$       $- 0.1$ (0.02)    $2.3 \times 10^{- 4}$   0.29
   cg10773601                              chr19   51226046    N_Shore              *CLEC11A*     TSS1500            85.8                                                         $- 1.4$ (0.3)     $2.3 \times 10^{- 7}$   $- 1.2$ (0.4)      $2.6 \times 10^{- 3}$       $- 1.7$ (0.4)     $8.0 \times 10^{- 5}$   0.52
  Top loci identified for male infants                                                                                                                                                                                                                                                                               
   cg22512536                              chr5    154134507   Island               *LARP1*       Body               1.9                                                          0.1 (0.03)        $1.7 \times 10^{- 2}$   0.1 (0.03)         $2.2 \times 10^{- 7}$       $- 0.01$ (0.04)   $7.9 \times 10^{- 1}$   0.002
   cg08964024                              chr12   14923326    Island               --            --                 1.6                                                          0.1 (0.02)        $4.1 \times 10^{- 3}$   0.1 (0.02)         $2.2 \times 10^{- 8}$       0.01 (0.02)       $7.8 \times 10^{- 1}$   0.002
  Top loci identified for female infants                                                                                                                                                                                                                                                                             
   cg04295372                              chr1    101184332   Open Sea             *VCAM1*       TSS1500            41.9                                                         0.9 (0.3)         $2.8 \times 10^{- 3}$   $- 0.1$ (0.6)      $8.5 \times 10^{- 1}$       1.6 (0.3)         $3.9 \times 10^{- 6}$   0.03
   cg09356083                              chr1    2430057     N_Shelf              *PLCH2*       Body               85.1                                                         $- 0.4$ (0.1)     $1.9 \times 10^{- 6}$   $- 0.3$ (0.2)      $4.4 \times 10^{- 2}$       $- 0.6$ (0.1)     $6.9 \times 10^{- 7}$   0.12
   cg20816789                              chr1    27462916    Open Sea             *SLC9A1*      Body               87.0                                                         $- 0.6$ (0.1)     $1.7 \times 10^{- 5}$   $- 0.5$ (0.3)      $5.2 \times 10^{- 2}$       $- 0.8$ (0.2)     $3.8 \times 10^{- 7}$   0.11
   cg22446399                              chr2    27326580    Open Sea             *CGREF1*      Body               95.9                                                         $- 0.3$ (0.1)     $1.5 \times 10^{- 3}$   $- 0.1$ (0.2)      $3.6 \times 10^{- 1}$       $- 0.5$ (0.1)     $4.2 \times 10^{- 6}$   0.06
   cg27403609                              chr2    11101403    Island               --            --                 91.8                                                         $- 0.5$ (0.3)     $4.8 \times 10^{- 2}$   0.1 (0.4)          $8.1 \times 10^{- 1}$       $- 1.2$ (0.3)     $3.4 \times 10^{- 4}$   0.004
   cg07248017                              chr4    8230689     Open Sea             *SH3TC1*      Body               71.1                                                         $- 0.6$ (0.2)     $2.1 \times 10^{- 4}$   $- 0.2$ (0.3)      $3.9 \times 10^{- 1}$       $- 1.0$ (0.2)     $1.2 \times 10^{- 6}$   0.009
   cg06239355                              chr5    32714010    Island               *NPR3*        Body               1.7                                                          0.1 (0.02)        $1.2 \times 10^{- 4}$   0.03 (0.04)        $4.0 \times 10^{- 1}$       0.1 (0.02)        $1.5 \times 10^{- 7}$   0.04
   cg15601915                              chr5    1065775     S_Shore              *SLC12A7*     Body               85.7                                                         $- 0.6$ (0.1)     $1.6 \times 10^{- 5}$   $- 0.4$ (0.2)      $6.4 \times 10^{- 2}$       $- 0.9$ (0.2)     $1.6 \times 10^{- 6}$   0.001
   cg17599748                              chr6    31589597    S_Shore              *SNORA38*     TSS1500            68.1                                                         $- 0.7$ (0.3)     $9.3 \times 10^{- 3}$   0.4 (0.4)          $2.9 \times 10^{- 1}$       $- 1.4$ (0.3)     $1.1 \times 10^{- 6}$   0.002
   cg08673909                              chr7    1329592     Island               --            --                 2.1                                                          $- 0.1$ (0.04)    $2.4 \times 10^{- 3}$   $- 0.01$ (0.1)     $8.5 \times 10^{- 1}$       $- 0.2$ (0.05)    $6.3 \times 10^{- 6}$   0.07
   cg10090217                              chr7    45151583    S_Shore              *TBRG4*       TSS1500            2.2                                                          $- 0.05$ (0.02)   $3.7 \times 10^{- 3}$   $- 0.004$ (0.03)   $9.0 \times 10^{- 1}$       $- 0.1$ (0.02)    $5.0 \times 10^{- 6}$   0.03
   cg16565528                              chr8    91010920    N_Shelf              --            --                 83.1                                                         0.8 (0.3)         $8.0 \times 10^{- 3}$   $- 0.1$ (0.4)      $8.4 \times 10^{- 1}$       1.8 (0.4)         $7.9 \times 10^{- 7}$   0.05
   cg03152353                              chr9    139417194   Island               *NOTCH1*      Body               56.6                                                         $- 0.6$ (0.2)     $1.4 \times 10^{- 3}$   $- 0.1$ (0.3)      $7.8 \times 10^{- 1}$       $- 1.1$ (0.2)     $4.6 \times 10^{- 7}$   0.02
   cg13817920                              chr9    96587843    N_Shore              --            --                 89.0                                                         $- 0.5$ (0.1)     $4.3 \times 10^{- 5}$   $- 0.5$ (0.2)      $9.1 \times 10^{- 3}$       $- 0.6$ (0.1)     $4.4 \times 10^{- 5}$   0.10
   cg13791644                              chr10   119794366   Open Sea             *RAB11FIP2*   Body               93.2                                                         0.5 (0.2)         $2.8 \times 10^{- 2}$   $- 0.1$ (0.3)      $7.9 \times 10^{- 1}$       1.0 (0.2)         $1.3 \times 10^{- 5}$   0.01
   cg18454045                              chr10   88391658    N_Shore              --            --                 69.2                                                         $- 0.6$ (0.2)     $8.0 \times 10^{- 3}$   0.1 (0.5)          $7.6 \times 10^{- 1}$       $- 1.3$ (0.3)     $2.8 \times 10^{- 7}$   0.004
   cg11127561                              chr11   125462151   N_Shore              *STT3A*       TSS1500            1.6                                                          0.1 (0.02)        $9.7 \times 10^{- 5}$   0.03 (0.02)        $1.8 \times 10^{- 1}$       0.1 (0.02)        $4.6 \times 10^{- 5}$   0.005
   cg17971003                              chr11   107582804   OpenSea              *SLN*         TSS200             93.3                                                         0.7 (0.2)         $1.5 \times 10^{- 4}$   0.4 (0.2)          $9.2 \times 10^{- 2}$       1.0 (0.2)         $1.7 \times 10^{- 6}$   0.18
   cg24637308                              chr11   6592297     Island               *DNHD1*       Body               76.2                                                         $- 3.3$ (0.9)     $9.1 \times 10^{- 5}$   $- 1.9$ (1.4)      $1.5 \times 10^{- 1}$       $- 4.3$ (0.9)     $1.1 \times 10^{- 6}$   0.12
   cg05959994                              chr13   114253916   Open Sea             *TFDP1*       Body               98.6                                                         $- 0.1$ (0.04)    $6.1 \times 10^{- 3}$   0.1 (0.05)         $1.1 \times 10^{- 1}$       $- 0.2$ (0.04)    $1.9 \times 10^{- 8}$   $2.9 \times 10^{- 8}$
   cg11203293                              chr13   25777762    Open Sea             --            --                 60.5                                                         $- 1.1$ (0.5)     $1.9 \times 10^{- 2}$   0.4 (0.7)          $5.5 \times 10^{- 1}$       $- 2.3$ (0.4)     $3.4 \times 10^{- 7}$   0.001
   cg04545835                              chr14   102675570   Open Sea             *WDR20*       Body               97.1                                                         $- 0.2$ (0.1)     $8.3 \times 10^{- 3}$   0.002 (0.2)        $9.9 \times 10^{- 1}$       $- 0.4$ (0.1)     $4.0 \times 10^{- 5}$   0.004
   cg08131309                              chr15   40399131    N_Shore              *BMF*         TSS1500            23.2                                                         $- 0.9$ (0.3)     $3.2 \times 10^{- 4}$   $- 0.1$ (0.4)      $7.1 \times 10^{- 1}$       $- 1.6$ (0.3)     $6.2 \times 10^{- 7}$   0.002
   cg04730825                              chr16   16116191    Open Sea             *ABCC1*       Body               58.7                                                         $- 0.8$ (0.3)     $9.2 \times 10^{- 3}$   0.1 (0.4)          $8.5 \times 10^{- 1}$       $- 1.7$ (0.4)     $3.8 \times 10^{- 6}$   0.02
   cg26686608                              chr16   88705716    N_Shore              *IL17C*       Body               41.5                                                         0.5 (0.2)         $2.2 \times 10^{- 2}$   $- 0.1$ (0.4)      $8.0 \times 10^{- 1}$       1.2 (0.3)         $1.7 \times 10^{- 6}$   0.0007
   cg00461015                              chr17   42295635    N_Shore              *UBTF*        5\'UTR             1.9                                                          $- 0.1$ (0.03)    $2.6 \times 10^{- 3}$   $- 0.02$ (0.04)    $6.6 \times 10^{- 1}$       $- 0.1$ (0.03)    $1.7 \times 10^{- 5}$   0.07
   cg04571282                              chr17   44108753    Open Sea             *KIAA1267*    3\'UTR             98.3                                                         $- 0.1$ (0.03)    $2.3 \times 10^{- 4}$   $- 0.1$ (0.1)      $3.6 \times 10^{- 1}$       $- 0.2$ (0.04)    $4.8 \times 10^{- 6}$   0.13
   cg11252953                              chr17   80358829    N_Shelf              *C17orf101*   Body               7.6                                                          0.4 (0.2)         $1.4 \times 10^{- 2}$   0.2 (0.3)          $5.5 \times 10^{- 1}$       0.8 (0.2)         $8.7 \times 10^{- 7}$   0.13
   cg15922057                              chr17   25784714    S_Shore              --            --                 31.8                                                         $- 0.6$ (0.3)     $3.4 \times 10^{- 2}$   0.2 (0.4)          $5.3 \times 10^{- 1}$       $- 1.2$ (0.3)     $8.9 \times 10^{- 6}$   0.001
   cg06753949                              chr19   15334309    Island               --            --                 1.9                                                          $- 0.1$ (0.03)    $2.3 \times 10^{- 4}$   $- 0.1$ (0.05)     $1.3 \times 10^{- 1}$       $- 0.2$ (0.04)    $7.8 \times 10^{- 6}$   0.27
   cg07780528                              chr19   35630334    N_Shelf              *FXYD1*       5\'UTR             23.3                                                         $- 0.5$ (0.1)     $3.1 \times 10^{- 4}$   $- 0.1$ (0.2)      $5.4 \times 10^{- 1}$       $- 0.8$ (0.2)     $2.0 \times 10^{- 6}$   0.15
   cg11610754                              chr19   18722595    Island               *TMEM59L*     TSS1500            1.7                                                          0.03 (0.01)       $2.7 \times 10^{- 3}$   $- 0.01$ (0.02)    $6.8 \times 10^{- 1}$       0.1 (0.01)        $3.1 \times 10^{- 6}$   0.03
   cg18598117                              chr19   941126      Island               *ARID3A*      Body               84.6                                                         $- 0.8$ (0.3)     $1.4 \times 10^{- 2}$   0.1 (0.8)          $9.0 \times 10^{- 1}$       $- 1.5$ (0.4)     $2.8 \times 10^{- 5}$   0.02
   cg22217660                              chr19   50765301    S_Shelf              *MYH14*       Body               92.2                                                         $- 0.3$ (0.1)     $2.0 \times 10^{- 2}$   0.1 (0.3)          $6.9 \times 10^{- 1}$       $- 0.7$ (0.2)     $1.2 \times 10^{- 5}$   0.04
   cg03373781                              chr20   30582113    N_Shore              *XKR7*        Body               74.8                                                         $- 0.7$ (0.2)     $3.8 \times 10^{- 4}$   $- 0.1$ (0.3)      $6.4 \times 10^{- 1}$       $- 1.1$ (0.2)     $2.3 \times 10^{- 7}$   0.02
   cg07341934                              chr20   57463711    Island               *GNAS*        3\'UTR             60.1                                                         $- 0.8$ (0.3)     $1.9 \times 10^{- 3}$   $- 0.3$ (0.5)      $5.5 \times 10^{- 1}$       $- 1.5$ (0.3)     $2.2 \times 10^{- 6}$   0.002
   cg21307155                              chr20   3216740     N_Shore              *SLC4A11*     Body               87.5                                                         $- 0.5$ (0.1)     $9.3 \times 10^{- 4}$   0.02 (0.2)         $9.1 \times 10^{- 1}$       $- 0.8$ (0.1)     $8.1 \times 10^{- 8}$   0.008
   cg17174023                              chr22   50987453    Island               *KLHDC7B*     1st Exon           9.0                                                          $- 0.6$ (0.2)     $1.5 \times 10^{- 2}$   0.2 (0.4)          $5.9 \times 10^{- 1}$       $- 1.0$ (0.3)     $3.1 \times 10^{- 5}$   0.05

Note: Body, gene body; Chr, Chromosome; FDR, false discovery rate; SE, standard error; TSS200, within 200 bps from transcription start site; TSS1500, within 1500 bps from transcription start site; UTR, untranslated region.

Average methylation in umbilical cord blood among all newborns.

The percent change in DNA methylation level for every doubling increase in prenatal maternal red blood cell lead concentrations. Adjusted for child sex, maternal age, maternal prepregnancy body mass index, maternal race, maternal educational level, maternal smoking status, parity, gestational age, and differential nucleated cell proportions (monocytes, ${\text{CD}8}^{+}$ T cells, ${\text{CD}4}^{+}$ T cells, natural killer cells, B cells, and nucleated red blood cells).

We identified somewhat different top loci in sex-specific EWAS analyses, and most of the loci had $p\,\text{values} < \; 0.05$ for interaction tests between infant sex and lead exposure ([Table 2](#t2){ref-type="table"}). Among male infants, methylation levels at only two CpGs in cord blood showed significant but small positive associations with maternal RBC lead at $\text{FDR} < \; 0.05$ ([Table 2](#t2){ref-type="table"}; see also Figure S2B). Neither of these two CpGs showed an association with prenatal lead in blood DNA collected in midchildhood (see Table S3). Among female infants, maternal RBC lead levels were negatively associated with methylation levels of 29 CpGs and were positively associated with DNA methylation at 9 CpGs in cord blood at $\text{FDR} < \; 0.05$ ([Table 2](#t2){ref-type="table"}; see also Figure S2C). One CpG (cg24637308) showed a strong negative association with prenatal lead exposure (the effect estimate was $- 4.3\%$ for each doubling of maternal RBC lead, $p = 1.1 \times 10^{- 06}$). This association also appeared to be linear over the lead exposure range ([Figure 1C](#f1){ref-type="fig"}) and was consistent in midchildhood, with each doubling of maternal RBC lead associated with 4.1% lower methylation in midchildhood females ($p = 0.003$). The CpG cg24637308 is located in the body of the Dynein Heavy Chain Domain 1 gene (*DNHD1*) and is annotated to a CpG island). Effect estimates for the other loci among female infants were either minor or were substantially attenuated in midchildhood. Visualization of regional DNA comethylation patterns for top loci showed that most CpGs around the *DNHD1* gene had similar changes in the same direction as that of the top CpG cg24637308 in association with lead exposure, although they did not pass the FDR adjustment ([Figure 2](#f2){ref-type="fig"}). Lists of annotated CpGs with uncorrected $p < 0.05$ in EWAS analyses and scatterplots for prenatal RBC lead levels and methylation levels at top loci other than cg10773601 and cg24637308 as shown in [Table 2](#t2){ref-type="table"} for all newborns, male infants, and female infants have been included in the Supplemental Material for reference (see Tables S4--S6; see also Figure S3). Sensitivity analyses excluding infants with sustained maternal smoking yielded generally similar results (see Tables S7--S9). Results from analyses with adjustment for the methylation score predicting smoking status were also generally consistent with the original results, and major top CpGs, including cg10773601 and cg24637308, still met $\text{FDR} < \; 0.05$ (see Tables S10--S12).

![Visualization of regional DNA comethylation patterns for genes *CLEC11A* (*A*) and *DNHD1* (*B*) in umbilical cord blood among all newborns. Black dots indicate the identified key loci (cg10773601 and cg24637308), blue dots indicate CpGs in the same direction, and red dots indicate CpGs in the opposite direction associated with lead exposure.](EHP1246_f2){#f2}

Because DNA methylation is tissue-specific, we were interested in examining the consistency of methylation patterns between our surrogate tissue (blood) and the potential target tissue (e.g., brain). We therefore investigated blood--brain DNA methylation correlations for top loci based on an independent sample dominated by adult females (the female:male ratio was approximately 2:1) ([@c13]) and found that blood DNA methylation at the cg24637308 locus (*DNHD1*) was highly correlated with methylation at the same locus in the prefrontal cortex ($r = 0.77$), the entorhinal cortex ($r = 0.78$), the superior temporal gyrus ($r = 0.75$) and the cerebellum ($r = 0.63$) ([Figure 3](#f3){ref-type="fig"}).

![Scatterplots and correlations for cg24637308 (*DNHD1* gene) methylation levels of blood DNA and four brain regions: prefrontal cortex (PC, $n = 74$), entorhinal cortex (EC, $n = 71$), superior temporal gyrus (STG, $n = 75$), and cerebellum (CE, $n = 71$), based on an independent data set dominated by females (the female:male ratio was approximately 2:1) from ([@c13]).](EHP1246_f3){#f3}

We also investigated the top loci identified by a previous EWAS analysis on prenatal lead exposure and cord blood DNA methylation ([@c10]) based on our data set and found that one of the loci (cg05374025) was significantly associated with prenatal lead exposure in our samples ($p = 0.031$; see Table S13).

*Bumphunting* analysis identified only one small DMR with two CpGs in chromosome 13 (chr13: 50194554--50194643) associated with RBC lead for all newborns \[family-wise error rate $\left( \text{FWER} \right) < 0.05$) and two DMRs in chromosome 6 (chr6: 29648271--29649084) and chromosome 5 (chr5: 135415819--135416613) for male infants ($\text{FWER} < \; 0.05$; see Table S14). However, these regions did not contain any of the top loci reported in [Table 2](#t2){ref-type="table"}.

Discussion {#s4}
==========

In this study of 268 U.S. mother--infant pairs, we found that prenatal RBC lead levels were associated with differential DNA methylation levels at several CpGs in umbilical cord blood. We also observed notable sex differences: RBC lead levels were associated with DNA methylation in more CpGs in female infants than in male infants. Most of the identified CpGs showed lower methylation levels in association with higher prenatal lead exposure. Estimated whole blood lead levels in our sample ($0.50\;\mu g/\text{dL}$) were slightly below the U.S. national average for women ($0.60\;\mu g/\text{dL}$) ([@c19]). Our results suggest that even at very low levels, prenatal lead exposure may be significantly associated with altered DNA methylation profiles in newborns.

Lead is a multiple-source pollutant well known for its adverse effects, and the main target organs of lead are the hematopoietic, nervous, and renal systems ([@c25]). Interestingly, we found that *in utero* lead exposure was associated with altered methylation levels at CpGs located within or near important regulatory genes of hematopoietic and nervous functions (i.e., *CLEC11A* and *DNHD1*). Lead is well known to interfere with hemoglobin synthesis and to affect erythrocyte morphology and survival ([@c35]). The gene *CLEC11A* encodes a secreted sulfated glycoprotein (CLEC11A) that functions as a growth factor for primitive hematopoietic progenitor cells ([@c24]). CLEC11A stimulates the proliferation and differentiation of hematopoietic precursor cells from various lineages, including RBCs, lymphocytes, granulocytes, and macrophages ([@c14]).

*DNHD1 (DYNC1H1)* is a member of the dynein heavy chain family and is highly expressed in the brain. Cytoplasmic dynein complex comprises subunits assembled on the DNHD1 dimer and is particularly important for neurons because it carries essential signals and organelles from distal sites to the cell body ([@c30]). Our results on *DNHD1* suggest that methylation changes in this gene may be potential targets of *in utero* lead exposure. Interestingly, there were strong correlations between blood--brain methylation for cg24637308 (*DNHD1*) based on another independent set of samples with a high proportion of female participants ([@c13]). Furthermore, the significant inverse association among female infants seemed consistent through midchildhood, highlighting the possibility of long-term programming effects of lead exposure. In support of our findings, previous studies have documented a strong link between lead exposure and impaired cognitive and behavioral functions ([@c4]; [@c22]; [@c38]).

Our study found substantial sex differences in lead exposure--associated methylation changes. It is plausible that the slightly higher RBC levels in mothers of female infants than in male infants may be partially responsible for the more significant CpGs found in female infants in the study, although the difference in exposure levels did not reach statistical significance. Similarly, our previous study on prenatal maternal lead and birth outcomes and another epidemiological study on prenatal lead and childhood body weight also did not find appreciable differences in lead exposure levels between the sexes despite the presence of different effect estimates associated with lead exposure in males and females ([@c1]; [@c26]). In light of the fact that several toxicological studies also observed appreciable effect differences between the sexes at the same doses of lead exposure ([@c5]; [@c38]), it is possible that the variation in the lead-associated effect spectrum over the sexes may be associated with sex-specific biological mechanisms rather than with the lead exposure doses. In addition, it has been shown that sex does influence genomic methylation status ([@c23]), yet little is known about sex differences in the regulation of the epigenome. Interestingly, a previous animal study found that the effects of lead exposure on DNMTs and DNA-binding proteins in the hippocampus appear to be different in males and females and are further differentiated by the period of development during which exposure occurs ([@c31]). The authors hypothesized that an interaction between genes and sex hormones during development, modified by lead exposure, may make specific brain regions such as the hippocampus differentially susceptible to methylation-associated modulation of transcriptional regulation. It is possible that the potential effects of lead exposure on epigenetic mechanisms, as observed in previous studies and in the present study, may contribute to a differential susceptibility between males and females to the adverse health outcomes reported in previous epidemiological and toxicological studies ([@c1]; [@c5]; [@c26]; [@c38]).

A previous study also investigated the epigenome-wide association of prenatal lead exposure with cord blood DNA methylation profiles in a birth cohort in rural Bangladesh ($n = 127$) with high environmental lead levels, and the authors identified a set of loci with $\text{FDR} < \; 0.05$~,~ among which some were located around the gene glycoprotein VI (*GP6*) ([@c10]). However, only one of these loci (cg05374025) reached statistical significance in our samples. It is notable that prenatal lead exposure levels were much higher in the Bangladesh cohort (mean maternal RBC lead level, $94\;\mu g/{kg}$) than in our U.S. samples (mean maternal RBC lead level, $1.22\;\mu g/\text{dL} \approx 12\;\mu g/{kg}$). In addition, several important participant characteristics differed substantially between the two study populations, including ethnic background and BMI (the median maternal BMI was $20{\,{kg}/m}^{2}$ in the Bangladesh cohort and $23{\,{kg}/m}^{2}$ in our cohort). Therefore, the potential adverse effect spectra and the action patterns of prenatal lead exposure may vary substantially between these two cohorts.

Our study has several strengths. We were able to prospectively investigate the methylation changes in association with prenatal lead exposure among male infants and female infants separately. We collected both cord blood samples and midchildhood blood samples, allowing us to examine the consistency of *in utero* lead exposure--DNA methylation associations over time. In addition, we were able to control for a number of covariates based on the detailed cohort follow-up information.

Our study also has several limitations. First, the distribution of lead exposure was relatively narrow, and the exposure levels were quite low. However, this range gave us the opportunity to investigate the potential effects of very low-level exposure, which represents common exposure levels in the United States and in other Western countries. Our results may not be generalizable to populations with different exposure ranges, or to lower-income and racial/ethnic minority populations. Second, our study measured maternal lead in RBC instead of in whole blood. Nevertheless, this is likely to be an accurate biomarker because 99% of whole-blood lead is found in RBC; thus, RBC lead is very highly correlated with whole-blood concentrations ([@c21]). Third, although lead is known to affect multiple organs, DNA methylation was measured using unfractionated blood collected at delivery and midchildhood---the only available biological sample. Whether the associations reported herein may reflect associations between *in utero* lead exposure and methylation at target organs is uncertain. However, peripheral blood is the major carrier of lead absorbed into the human body, and peripheral blood cells contact and react directly with the internal forms of lead ([@c7]). Furthermore, there are strong correlations between blood and brain methylation for the CpG cg24637308 on the body of the *DNHD1* gene, suggesting that peripheral blood may serve well as a surrogate tissue for the target organ brain for certain key regulatory loci. Fourth, we were unable to investigate the exact biological mechanisms behind the observed methylation changes associated with prenatal lead exposure. Although lead exposure has been found to reduce the global DNA methylation level by noncompetitive inhibition and alteration of DNMT ([@c29]), this would not explain why not all affected genes are in the negative direction. Further studies are needed to investigate this issue in detail. Fifth, we were unable to validate the methylation changes associated with lead exposure using another method, such as gene expression assays or pyrosequencing assays, owing to the unavailability of extra biological samples. Nevertheless, the visualization of regional DNA comethylation patterns for potential target genes reveals generally consistent change patterns for CpGs in these genes, strengthening the validity of the reported results. Finally, we aimed to examine the potential effects of *in utero* lead exposure and did not include lead exposures after birth and before midchildhood; whether the associations between prenatal lead exposure and methylation in midchildhood may be confounded by other exposures is unknown. However, early pregnancy is a critical time window for epigenetic programming in the fetus, and it is during this time period that adverse *in utero* exposures are of most interest in relation to DNA methylation programming.

Conclusion {#s5}
==========

Based on an EWAS of relatively low levels of prenatal lead exposure and DNA methylation in a prospective prebirth cohort, we identified several CpGs of biological relevance for effects of *in utero* exposure to lead. There were sex-specific differences in the top CpGs associated with prenatal lead exposure, suggesting a potential susceptibility difference in relation to lead exposure between males and females. Further studies are needed to replicate our findings and to investigate their relevance to specific adverse health outcomes. Pending further investigation, our results suggest that prenatal lead exposure, even at very low levels, may modify the DNA methylation profiles in offspring, providing a mechanistic explanation for previously reported adverse postpartum health outcomes of prenatal lead exposure.
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